BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025

Rhea-AI Summary

BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors throughout the event.

The company, which pioneers the patented Botanical Synthesis technology platform, views this as a significant opportunity to showcase its growth trajectory. Following their Nasdaq listing and the launch of their CDMO Services Division, BioHarvest has achieved notable milestones, including:

• VINIA product reaching $50 Million in cumulative sales
• Advancement in CDMO Services division research for plant-based solutions
• Partnerships with pharmaceutical, nutraceutical, cosmetics, and nutrition sectors

News Market Reaction

-1.68%

1 alert

-1.68% News Effect

On the day this news was published, BHST declined 1.68%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 37th Annual Roth Conference taking place on March 16-18, 2025.

CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event.

37th Annual Roth Conference for Growth Companies
Date: March 16-18, 2025
Location: Laguna Cliffs Marriott Resort & Spa - Dana Point, CA
Format: 1x1s Meetings

Sobel said: "I am pleased to announce our invitation to the 37th Annual Roth Conference, which is a high-profile opportunity to showcase BioHarvest's transformative growth story. Following our recent Nasdaq listing and the launch of our CDMO Services Division last year, we are well positioned to execute on our mission to commercialize life-changing, plant-based compounds. These efforts have resulted in major milestones in our direct-to-consumer business, where we recently announced that VINIA had reached $50 Million in cumulative sales, and in our CDMO Services division, where we are conducting research on impactful plant-based solutions for our industry partners in the pharmaceutical, nutraceutical, cosmetics, and nutrition sectors."

Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact MZ Group at BHST@mzgroup.us.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

This press release may contain "forward-looking statements". "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and any other risks identified in other filings made by the Company with the Securities and Exchange Commission.

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHST@mzgroup.us

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243529

FAQ

When and where is BioHarvest Sciences (BHST) presenting at the Roth Conference 2025?

BioHarvest Sciences will participate in the 37th Annual Roth Conference from March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA.

What major sales milestone has BHST's VINIA product achieved?

VINIA has reached $50 Million in cumulative sales according to the announcement.

What are the key business segments of BioHarvest Sciences (BHST)?

BioHarvest operates through its direct-to-consumer business featuring VINIA products and its CDMO Services Division, which develops plant-based solutions for various industry partners.

Which industries does BioHarvest's (BHST) CDMO Services Division serve?

The CDMO Services Division serves partners in the pharmaceutical, nutraceutical, cosmetics, and nutrition sectors.

What is the format of BHST's participation at the 2025 Roth Conference?

CEO Ilan Sobel will host one-on-one meetings with institutional investors throughout the conference.